Drug Profile

Research programme: interleukin 12 replacement therapeutics - XOMA

Alternative Names: IL-12 - XOMA; Interleukin-12 - XOMA

Latest Information Update: 02 Mar 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Alkermes plc
Developer XOMA
Class Antineoplastics; Immunotherapies; Interleukins
Mechanism of Action Interleukin 12 replacements

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Preclinical Cancer

Most Recent Events

13 Nov 2024 Mural Oncology plans to nominate development candidate in Q4 2024
15 Apr 2024 Pharmacodynamics data from a preclinical study in Cancer released by Mural Oncology
05 Mar 2024 Preclinical trials in Cancer in Ireland (Parenteral), prior to March 2024

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com